Synthetic cannabinoid-induced delirium
Synthetic cannabinoid-induced delirium is characterized by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of synthetic cannabinoids. The amount and duration of synthetic cannabinoid use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioral and neurodevelopmental disorders.
ICD-11 diagnostic criteria
- zaburzenia świadomości
- związek z używaniem syntetycznych kannabinoidów
How to recognise
In the ICD-11 framework, the core symptoms taken into account when recognising Synthetic cannabinoid-induced delirium are:
- dezorientacja
Differential diagnosis
When diagnosing Synthetic cannabinoid-induced delirium, the following ICD-11 disorders should be considered in the differential diagnosis:
Frequently asked questions
How is Synthetic cannabinoid-induced delirium diagnosed according to ICD-11?
According to ICD-11, the diagnostic criteria for Synthetic cannabinoid-induced delirium (6C42.5) include: zaburzenia świadomości; związek z używaniem syntetycznych kannabinoidów.
What disorders are in the differential diagnosis of Synthetic cannabinoid-induced delirium?
The differential diagnosis of Synthetic cannabinoid-induced delirium (6C42.5) includes: Zaburzenia związane z używaniem kannabinoidów pochodzenia roślinnego (6C41).
WHO ICD-11 source
View this entry in the official WHO ICD-11 browser: 6C42.5 – WHO ICD-11
Notes
Proszę zakodować również jednostkę chorobową (schorzenie) będące przyczyną
Open in interactive browser →